Long Term Effect of High-intensity Training After Heart Transplantation

January 22, 2016 updated by: Marianne Yardley, Oslo University Hospital

High-intensity training (HIT) has repeatedly been documented to have superior positive effects compared to moderate exercise in patients with coronary heart disease and heart failure. Since heart transplant recipients (HTx), have a denervated heart with different respond to exercise, HIT has previously not been introduced among these patients. Rikshospitalet carried out a RCT to investigate this (the TEX study 2009-2012), and found that this form of exercise also was highly effective and safe in long term HTx with clinically significant improvement in VO2peak, muscular exercise capasity, general HRQoL, and even slower progression of CAV (coronary allograft vasculopathy). Based on these findings we ask the following questions in this follow-up study:

  1. Would the effect on VO2peak, HRQoL,muscle capacity and CAV obtained during the study period continue during long term follow up (5 years)?
  2. Is the intervention group more physical active after HIT compared to the control group?

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

41

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
      • Oslo, Norway, 0424
        • OUS- Rikshospitalet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The TEX population.

Description

Inclusion Criteria:

  • stable situation
  • optimal medical treatment
  • written concent

Exclusion Criteria:

  • unstable situation,
  • infections (open wounds or skin diseases),
  • physical conditions that prevents participation,
  • or other injuries/ diseases who are contraindicated with training.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention group
Group that followed high- intensity interval training program in TEX study.
Control group
Followed up on a regular basis for HTx recipients in Norway.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
mean VO2peak in the intervention group and control group
Time Frame: 5 years after start of inclusion in RCT (TEX). One measurment.
We will use the same test protocol as the TEX- study.
5 years after start of inclusion in RCT (TEX). One measurment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
How many has progression of cardiac allograft vasculopathy in the intervention group and control group.
Time Frame: 5 years after inclusion in RCT (TEX study).
Progression of vasculopathy will be studied with IVUS technique, and compared with IVUS pictures from TEX.
5 years after inclusion in RCT (TEX study).
Mean muscle capacity in the intervention group and control group.
Time Frame: 5 years after inclusion in RCT, TEX study.
5 years after inclusion in RCT, TEX study.
Quality of life
Time Frame: 5 years after inclusion in TEX- study.
We will use validated questionnaires to estimate quality of life and to evaluate depression.
5 years after inclusion in TEX- study.
Difference in activity level between groups
Time Frame: 5 years after inclusion i RCT, TEX study.
To estimate activity the study population will fill out a validated questionnaire about physical activity, and they will wear a physical activity monitor at home for one week.
5 years after inclusion i RCT, TEX study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oslo University Hospital

Collaborators

Norwegian Health Association

Investigators

  • Study Director: Lars Gullestad, professor, OUS- kardiologisk avdeling

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2014

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

August 8, 2014

First Submitted That Met QC Criteria

August 8, 2014

First Posted (Estimate)

August 11, 2014

Study Record Updates

Last Update Posted (Estimate)

January 25, 2016

Last Update Submitted That Met QC Criteria

January 22, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 2014/872/REK sør-øst C

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Transplant Recipients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe